Aquestive Therapeutics, Inc. (AQST)

4d ago, source: Yahoo Finance

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company ...

Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals

1mon ago, source: Hosted on MSN

Aquestive Therapeutics, Inc. AQST shares jumped 16% on Mar 15 after the company achieved the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of ...

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

25d ago, source: Business Insider

WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company ...

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Business Insider

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal cl ...

Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

20d ago, source: ADVFN

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to ...

Aquestive Therapeutics Inc AQST

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aquestive Therapeutics Inc AQST

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aquestive Therapeutics Inc (AQST)

4d ago, source: Investing

On Thursday, Piper Sandler initiated coverage on shares of Aquestive Therapeutics (NASDAQ:AQST), assigning an Overweight rating with a price target of $10. The firm highlighted ...

Aquestive Therapeutics Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Aquestive Therapeutics Inc (AQST)

20d ago, source: Investing

Pre-Open Stock Movers: Sidus Space Inc (NASDAQ:SIDU) 54% HIGHER; announced that it has signed a launch agreement with SpaceX for five launches, beginning in early 2023. UiPath ...